Industry Strength Score
65/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
RAPPORT THERAPEUTICS INC (RAPP) Stock Price & Overview
NASDAQ:RAPP • US75383L1026
Current stock price
32.87 USD
-0.87 (-2.58%)
Last:
The current stock price of RAPP is 32.87 USD. Today RAPP is down by -2.58%. In the past month the price increased by 21.85%. In the past year, price increased by 197.79%.
RAPP Key Statistics
52-Week Range7.73 - 42.27
Current RAPP stock price positioned within its 52-week range.
1-Month Range28.13 - 40.92
Current RAPP stock price positioned within its 1-month range.
- Market Cap
- 1.571B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.86
- Dividend Yield
- N/A
RAPP Stock Performance
Today
-2.58%
1 Week
-8.69%
1 Month
+21.85%
3 Months
+26.79%
Longer-term
6 Months +16.63%
1 Year +197.79%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
RAPP Stock Chart
RAPP Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to RAPP. When comparing the yearly performance of all stocks, RAPP is one of the better performing stocks in the market, outperforming 96.95% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
RAPP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RAPP. RAPP has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RAPP Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 10, 2026
PeriodQ4 / 2025
EPS Reported-$0.72
Revenue Reported
EPS Surprise -4.11%
Revenue Surprise %
RAPP Forecast & Estimates
16 analysts have analysed RAPP and the average price target is 53.27 USD. This implies a price increase of 62.05% is expected in the next year compared to the current price of 32.87.
Analysts
Analysts85
Price Target53.27 (62.06%)
EPS Next Y-19.13%
Revenue Next YearN/A
RAPP Index Membership
RAPP is currently included in the following stock indexes tracked on ChartMill.
RAPP Financial Highlights
Over the last trailing twelve months RAPP reported a non-GAAP Earnings per Share(EPS) of -2.86. The EPS decreased by -29.51% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-111.48M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.76% | ||
| ROE | -23% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-26.32%
Sales Q2Q%N/A
EPS 1Y (TTM)-29.51%
Revenue 1Y (TTM)N/A
RAPP Ownership
Ownership
Inst Owners106.28%
Shares47.79M
Float44.95M
Ins Owners4.58%
Short Float %7.59%
Short Ratio9.75
RAPP Industry Overview
RAPP operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
17/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
62%
Outperformed 62% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 4.4%
- New Lows
- 4.4%
- Average ROE
- 50.6%
- Average Profit Margin
- 27.8%
- Average Operating Margin
- 37.5%
- Average P/E
- 25.1
- Average Fwd P/E
- 19.8
- Average Debt/Equity
- 1.2
RAPP Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 24.41 | 825.773B | ||
| JNJ | JOHNSON & JOHNSON | 17.96 | 548.657B | ||
| MRK | MERCK & CO. INC. | 21.71 | 271.761B | ||
| PFE | PFIZER INC | 8.79 | 150.628B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.17 | 118.952B | ||
| ZTS | ZOETIS INC | 16.07 | 49.054B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 28.582B | ||
| VTRS | VIATRIS INC | 6.01 | 17.257B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 20.78 | 11.061B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.463B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.11B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.955B | ||
| CORT | CORCEPT THERAPEUTICS INC | 86.76 | 4.959B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RAPP
Company Profile
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The company is headquartered in Boston, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2024-06-07. The company has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The company is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Company Info
IPO: 2024-06-07
RAPPORT THERAPEUTICS INC
99 High Street, Suite 2100
Boston MASSACHUSETTS US
Employees: 84
Phone: 18573218020
RAPPORT THERAPEUTICS INC / RAPP FAQ
What does RAPP do?
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The company is headquartered in Boston, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2024-06-07. The company has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The company is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
What is the current price of RAPP stock?
The current stock price of RAPP is 32.87 USD. The price decreased by -2.58% in the last trading session.
Does RAPPORT THERAPEUTICS INC pay dividends?
RAPP does not pay a dividend.
How is the ChartMill rating for RAPPORT THERAPEUTICS INC?
RAPP has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is RAPPORT THERAPEUTICS INC (RAPP) stock traded?
RAPP stock is listed on the Nasdaq exchange.
When does RAPPORT THERAPEUTICS INC (RAPP) report earnings?
RAPPORT THERAPEUTICS INC (RAPP) will report earnings on 2026-05-07.